{"id":"W2058887247","doi":"10.1016/j.jhep.2012.06.014","title":"Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial","year":2012,"lang":"en","type":"article","venue":"Journal of Hepatology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":821,"is_retracted":false,"has_abstract":true,"ca_institutions":"Toronto General Hospital","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Instituto de Salud Carlos III; Bayer HealthCare; Onyx Pharmaceuticals; National Institutes of Health; Ministerio de Ciencia e Innovación; European Commission","keywords":"Sorafenib; Medicine; Internal medicine; Hepatocellular carcinoma; Placebo; Hazard ratio; Adverse effect; Subgroup analysis; Oncology; Randomized controlled trial; Gastroenterology; Surgery; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007572237,0.001433684,0.002513858,0.0003454517,0.0003317894,0.001079135,0.0005090061,0.0005770153,0.00203883],"category_scores_gemma":[0.005187852,0.0003843254,0.005529212,0.0006697634,0.0004827448,0.0007324273,0.0005421788,0.001836306,0.0003437133],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007770708,"about_ca_system_score_gemma":0.001398364,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005341312,"about_ca_topic_score_gemma":0.001576434,"domain_scores_codex":[0.9974232,0.001683364,0.0002404781,0.0002731064,0.0001997306,0.0001801898],"domain_scores_gemma":[0.9963141,0.001188995,0.001131898,0.0005127047,0.00034102,0.0005113094],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.8918945,0.003384949,0.01774818,0.001535414,0.02446555,0.00008300789,0.0001580597,0.001272149,0.004672987,0.0001585023,0.002708575,0.05191813],"study_design_scores_gemma":[0.780633,0.09574205,0.08841199,0.0002316239,0.0246742,0.0002363572,0.0001151015,0.001573806,0.002536247,0.0009967468,0.004774712,0.00007418034],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9690728,0.02148143,0.001346947,0.0006515011,0.0002540844,0.002709404,0.002084033,0.00008541374,0.002314407],"genre_scores_gemma":[0.9876533,0.004484632,0.001131594,0.0006480329,0.0003143137,0.001986137,0.002992076,0.00002809836,0.0007617093],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007572237,"threshold_uncertainty_score":0.04004627,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03640248984324077,"score_gpt":0.2820490078989289,"score_spread":0.2456465180556881,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}